Drug Profile
Indotecan - Gibson Oncology
Alternative Names: LMP-400; NSC-724998; NSC-743400Latest Information Update: 04 Jan 2022
Price :
$50
*
At a glance
- Originator Linus Oncology; National Cancer Institute (USA); Purdue University
- Developer Gibson Oncology; National Cancer Institute (USA)
- Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Eye disorder therapies; Isoquinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Colorectal cancer; Ewing's sarcoma; Solid tumours
- Discontinued Lymphoma
Most Recent Events
- 04 Jan 2022 Indotecan - Gibson Oncology is available for licensing as of 04 Jan 2022. https://gibsononcology.com/our-pipeline/
- 24 Jun 2021 Phase-I clinical trials in Solid tumours is ongoing in USA (Gibson Oncology pipeline, June 2021)
- 30 Sep 2020 Phase-II clinical trials in Ewing's Sarcoma (In children) in USA (IV) (Gibson Oncology pipeline, June 2021)